<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 27 Apr 2021 19:22:53 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>两项临床新进展，不一样的CDK4/6抑制剂Trilaciclib</title><link>https://mp.weixin.qq.com/s/vjcr2inEki-djSyKHlnoGQ</link><description></description><content:encoded><![CDATA[两项临床新进展，不一样的CDK4/6抑制剂Trilaciclib]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>直播预告 | 立足2020，展望2021-中国医药行业十大发展趋势</title><link>https://mp.weixin.qq.com/s/WsIXrsDR4lzOJetv0OWYcg</link><description></description><content:encoded><![CDATA[直播预告 | 立足2020，展望2021-中国医药行业十大发展趋势]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>华东医药4.9亿收购道尔生物75%股权，加码抗体药物开发</title><link>https://mp.weixin.qq.com/s/MacXdS-RQUrwnmAu2VdpBA</link><description></description><content:encoded><![CDATA[华东医药4.9亿收购道尔生物75%股权，加码抗体药物开发]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>爱思迈生物申报CD20/CD3双抗，国内第3家</title><link>https://mp.weixin.qq.com/s/dRTv8YmlUj1C_8BA6NJ0cw</link><description></description><content:encoded><![CDATA[爱思迈生物申报CD20/CD3双抗，国内第3家]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>奥赛康申报ALK 5抑制剂，国内第5家</title><link>https://mp.weixin.qq.com/s/jQCVVSRDIKv5xS7H03M-BA</link><description></description><content:encoded><![CDATA[奥赛康申报ALK 5抑制剂，国内第5家]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>原料药断供，一企业拒绝履行集采中选义务</title><link>https://mp.weixin.qq.com/s/K8Qb5w-l0389l_1dBp31nA</link><description></description><content:encoded><![CDATA[原料药断供，一企业拒绝履行集采中选义务]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>黑龙江“8省2区”集采来袭，21个未过评品种带量采购</title><link>https://mp.weixin.qq.com/s/G_AFTVsmYTXVJmfaMozt8Q</link><description></description><content:encoded><![CDATA[黑龙江“8省2区”集采来袭，21个未过评品种带量采购]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>今日，强生2款新药申报临床</title><link>https://mp.weixin.qq.com/s/Mdw-STOWbZHe8rkn6ESJAg</link><description></description><content:encoded><![CDATA[今日，强生2款新药申报临床]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>全球首个CD38单抗新适应症即将在华获批，2020年销售额41.9亿美元</title><link>https://mp.weixin.qq.com/s/ENd_IZi2B7XvfVnl3pkRDg</link><description></description><content:encoded><![CDATA[全球首个CD38单抗新适应症即将在华获批，2020年销售额41.9亿美元]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>医药魔方征稿 | 分享真知灼见，碰撞思维火花！</title><link>https://mp.weixin.qq.com/s/BFxI6mHdYVj71kFkUIrh6A</link><description></description><content:encoded><![CDATA[医药魔方征稿 | 分享真知灼见，碰撞思维火花！]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>魔方研报分享 | 2020中国医药市场回顾—销售市场篇</title><link>https://mp.weixin.qq.com/s/wVxum9BDzbR0R1vca59DxQ</link><description></description><content:encoded><![CDATA[魔方研报分享 | 2020中国医药市场回顾—销售市场篇]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>罗氏PD-L1第3项适应症即将获批！一线治疗NSCLC</title><link>https://mp.weixin.qq.com/s/cd8AsntNVlupMnAqc5cFPQ</link><description></description><content:encoded><![CDATA[罗氏PD-L1第3项适应症即将获批！一线治疗NSCLC]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>今日，12款仿制药通过一致性评价，5款为首家</title><link>https://mp.weixin.qq.com/s/S_bPcFpSSz3T55onQflqDA</link><description></description><content:encoded><![CDATA[今日，12款仿制药通过一致性评价，5款为首家]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>优效于阿普斯特！百时美施贵宝first-in-class 口服TYK-2抑制剂两项III期研究结果公布（附PPT）</title><link>https://mp.weixin.qq.com/s/lY-v1E2aZ1CePAAIMbmKjA</link><description></description><content:encoded><![CDATA[优效于阿普斯特！百时美施贵宝first-in-class 口服TYK-2抑制剂两项III期研究结果公布（附PPT）]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>博安生物在《Nature》杂志子刊发表新冠中和抗体研究成果</title><link>https://mp.weixin.qq.com/s/wS6YjNEv-JI74X9LEH5vaw</link><description></description><content:encoded><![CDATA[博安生物在《Nature》杂志子刊发表新冠中和抗体研究成果]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>直播预告 | 2021年3月全球新药研发进展</title><link>https://mp.weixin.qq.com/s/5Eay5koAA1MZLRZ3UnG2tw</link><description></description><content:encoded><![CDATA[直播预告 | 2021年3月全球新药研发进展]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>魔方研报分享 | 2020中国医药市场回顾—重磅政策分析篇</title><link>https://mp.weixin.qq.com/s/wX-MAq4l45GK-0zolryV9Q</link><description></description><content:encoded><![CDATA[魔方研报分享 | 2020中国医药市场回顾—重磅政策分析篇]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>罗氏2021第1季度业绩：总收入149.3 亿瑞士法郎，新产品持续发力，占制药业务50%</title><link>https://mp.weixin.qq.com/s/cQjb9IJfo-FAhQpx1AylHg</link><description></description><content:encoded><![CDATA[罗氏2021第1季度业绩：总收入149.3 亿瑞士法郎，新产品持续发力，占制药业务50%]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>20年来首个全新机制抗流感新药！罗氏Xofluza即将获批上市</title><link>https://mp.weixin.qq.com/s/2piuZojxSukm14M5V2CX6g</link><description></description><content:encoded><![CDATA[20年来首个全新机制抗流感新药！罗氏Xofluza即将获批上市]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>首款CD19 ADC获FDA批准上市</title><link>https://mp.weixin.qq.com/s/ZgUWPacvPhl-9ynKIEfemQ</link><description></description><content:encoded><![CDATA[首款CD19 ADC获FDA批准上市]]></content:encoded><pubDate>Sat, 24 Apr 2021 10:27:28 +0800</pubDate></item></channel></rss>